tbuckley/cabot-search huggingface dataset:
SAT0465 Osteopenic Syndrome and Atherosclerosis of Extracranial Arteries among Males with Coronary Heart Disease
Authors: E. Malyuta, P. Korchuganov, A. Voronkina, T. Raskina, J. Averkieva, A. Kokov, O. Barbarash
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Objectives</h3> To examine the relationship between atherosclerosis of extracranial arteries and indicators of bone mineral density (BMD) among men with coronary heart disease (CHD). <h3>Methods</h3> 74 males with angiographically verified CHD were examined. BMD was assessed by dual energy absorptiometry (densitometer Exsell XR-46, Norland, the USA) with the definition of T-criterion of the proximal femur and lumbar spine (L<sub>I</sub>-L<sub>IV</sub>). Radiopaque selective coronarography and duplex scanning of the extracranial arteries were carried out using "Aloka α-110". Artery narrowing was considered hemodynamically significant that was more than 50% of its diameter. The intima-media thickness (IMT) more than 1.0 mm was regarded as carotid atherosclerosis. For quantitative trait results are presented as the median (Me) with interquartile intervals (25%,;75% percentile). Depending on the values of the T-criterion, patients were divided into 2 groups: I - with osteopenic syndrome including directly osteoporosis and subclinical state of "osteopenia" (53 patients), age 59 (52; 68) years; II - with normal BMD (21 patients), age 58 (54; 66) years. <h3>Results</h3> The thickness of the intima-media in group I was 1,1 (1,0; 1,2) mm, in group II – 1,0 (0,9; 1,1 mm), p&gt;0,05. IMT more than 1,0 mm identify 68,0% in group I and 47,6% in group II, p&gt;0.05. Defeat of three or more extracranial arteries among patients with osteopenic syndrome occurred more frequently (10,2%), than among patients with normal BMD (5.0%), p&gt;0.05. Patients I and II groups did not differ for any stenosis (58, 0% and 38.1%, respectively, p&gt;0.05), while severe stenosis (more than 50%) significantly more often detected among patients with osteopenic syndrome (24,2%) compared to the group with normal BMD (5,5%), p&lt;0.05. The median % of stenosis was 28% (0; 65) in group I and 0 (0; 27,5) in group II, p&gt;0.05. The weak strength correlation was revealed between the ratio T-criterion of the femoral neck and the presence of left internal carotid artery stenosis (r= -0,3; p&lt;0,05), as well as an indicator of the T-criterion of the femoral neck and IMT (r= -0,32; p&lt;0.01), BMD proximal femur and IMT (r= -0,31; p&lt;0,05). <h3>Conclusions</h3> Reduced bone mineral density among men is associated with hemodynamically significant lesion and correlates with the severity of atherosclerosis of extracranial arteries. These results confirm the likelihood of common pathogenetic mechanisms of osteopenic syndrome and atherosclerotic lesions of the brachiocephalic arteries. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4015
ASSESSMENT OF LEFT ATRIAL VOLUMES BY 3D CT ANGIOGRAPHY AND 2D ECHOCARDIOGRAPHY IN PATIENTS UNDERGOING ATRIAL FIBRILLATION ABLATION
Authors: Abhimanyu Teja Yarramaneni, Jennifer Conroy, Joseph Flanagan, John Tang, Simcha Pollack, Elana Koss, Lin Wang, Nathaniel Reichek, Jane Cao, Madhavi Kadiyala
Journal: Journal of the American College of Cardiology (2015)
AT-54 * THERMOTHERAPY WITH COATED IRON OXIDE NANOPARTICLES RADIOTHERAPY VERSUS RADIOTHERAPY ALONE IN RECURRENT GLIOBLASTOMA: AN OPEN-LABEL RANDOMIZED CONTROLLED STUDY
Authors: W. Stummer, R. Goldbrunner, J. Wolfer
Journal: Neuro-Oncology (2014)

INTRODUCTION: Limited therapeutic options are available for glioblastoma, the most frequent and malignant brain tumor, after failure of first-line therapy. Therefore, corresponding new antitumor therapies are urgently needed. Hyperthermia and thermoablation kill, disable or sensitize tumor cells to concurrent anticancer treatment depending on duration and temperature, and possibly inhibit the cell's repair system. This clinical safety and efficacy study investigates thermotherapy after stereotactic injection of biocompatible aminosilane-coated superparamagnetic iron oxide nanoparticles into the tumor. These particles, which agglomerate immediately after injection, are stimulated by an external alternating magnetic field, thus generating heat within the tumor while sparing the surrounding healthy tissue. Feasibility, safety, and first efficacy results in combination with radiotherapy have been shown previously. METHODS: NanoTherm monotherapy is evaluated in a run-in phase (24 subjects) and, if effective, in the main study versus a combination with hypofractionated stereotactic radiotherapy (HFSRT) and HFSRT alone in 285 subjects in recurrent glioblastoma. Major eligibility criteria are radiographically and histologically confirmed first progression of supratentorial glioblastoma, a maximum tumor volume of 25 ml, standard radiochemotherapy or radiotherapy alone, at least 6 months off RT, no proximate metallic material, and no previous and concurrent antiangiogenics. After stereotactic deposition of nanoparticle depots in the tumor, six 1-hourly alternating magnetic field sessions are applied twice weekly within 2 h after HFSRT, which is applied as 2.66 Gy fractions (40 Gy in total) 5 days a week for 3 weeks. Patients are followed-up every 3 months for survival, the primary study endpoint. Study accrual began in January 2014.
Occult Colon Cancer With Initial Cutaneous Metastatic Manifestation
Authors: Vien X. Nguyen, Ba D. Nguyen, Panol C. Ram
Journal: Clinical Nuclear Medicine (2012)

Skin metastasis as initial clinical presentation of occult internal organ malignancy is of rare occurrence, predominantly encountered in breast and lung cancer. The search for the occult causative primary malignancy is usually difficult with conventional anatomy-based cross-sectional imaging. The authors present a case of cecal cancer with thoracic and abdominal cutaneous metastasis demonstrated by PET/CT.
Symptomatic Cerebral Hyperperfusion on SPECT After Indirect Revascularization Surgery for Moyamoya Disease
Authors: Won-Sang Cho, Ho-Young Lee, Hyun-Seung Kang, Jeong Eun Kim, Jae Seung Bang, Chang-Wan Oh
Journal: Clinical Nuclear Medicine (2012)

Six patients who experienced transient neurological deteriorations with no evidences of hemorrhage and infarction after encephaloduroarteriogaleosynangiosis for moyamoya disease were evaluated with semiquantitative analysis using brain perfusion SPECT. Postoperative transient neurological deteriorations topographically corresponded to hyperperfusion areas on SPECT. Cerebral blood flows of both the operated hemisphere and focal hyperperfusion area increased significantly after surgery (P=0.046 and 0.028, respectively), compared with the preoperative ones. Symptomatic cerebral hyperperfusion may occur transiently after indirect revascularization surgery for adult moyamoya disease. Further study is needed to clarify the exact mechanism of cerebral hyperperfusion after indirect surgery.
Endoscopic retrograde cholangiopancreatography (ERCP) for intradiverticular papilla: endoclip-assisted biliary cannulation
Authors: C. Huang, Y. Tsou, C. Lin, J. Tang
Journal: Endoscopy (2010)

An intradiverticular papilla (IDP) can make biliary cannulation difficult during endoscopic retrograde cholangiopancreatography (ERCP), and endoscopists sometimes need to use special techniques to achieve deep common bile duct (CBD) cannulation [1] [2] [3]. We describe two difficult IDP cases in which successful biliary cannulation was achieved after using endoclips to facilitate a temporary change in the anatomical position of the major papilla.
Importance of Node Dissection in Relation to Neoadjuvant and Adjuvant Therapy
Authors: William C. Huang, Bernard H. Bochner
Journal: Journal of the National Comprehensive Cancer Network (2006)

Since the advent of effective chemotherapeutic regimens for treating transitional cell carcinoma, multimodal therapy has become part of the contemporary management of patients with muscle-invasive bladder cancer. However, radical cystectomy with pelvic lymphadenectomy remains the cornerstone of treatment for patients with localized and regionally advanced muscle-invasive disease. The effectiveness of chemotherapy models in bladder cancer can depend greatly on the quality of surgery. Unfortunately, without sufficient level I data, the boundaries of lymphadenectomy and the diagnostic and therapeutic ramifications of variations in the pelvic lymph node dissection remain undetermined. This article examines the role of pelvic lymph node dissection during perioperative chemotherapy and discusses the current challenges in establishing standards for lymphadenectomy in patients undergoing treatment for muscle-invasive bladder cancer.
PTU-115 Hepatitis B in Pregnancy: what Happens to the Infants?
Authors: J Dyson, J Waller, E Michael, A Turley, S Moses, M Valappil, M Hudson, M Bassendine, S McPherson
Journal: Gut (2013)

<h3>Introduction</h3> Antenatal screening for Hepatitis B (HBV) has been offered to all pregnant women in the UK since 2000. Immunoprophylaxis of infants is essential to reduce the risk of vertical transmission. It is recommended that HBV vaccination (4 serial doses) be given to all infants born to HBV positive mothers. In addition, Hepatitis B immunoglobulin (HBIG) is recommended for infants of Hepatitis B e antigen (HBeAg) positive mothers. Infants should have post-vaccination testing between 9–18 months. Hepatitis B surface antigen (HBsAg) negative infants with anti-HBs levels &gt; 10iu/ml need no further management. If anti-HBs is &lt; 10iu/ml infants should receive a second vaccination series. Our aim was to evaluate the management of infants born to HBV positive mothers. <h3>Methods</h3> All HBV positive pregnant women seen in our hospital between January 2008 and November 2011 were identified from an obstetric database. We examined if the infants received the recommended vaccinations, HBIG and post-vaccination testing. <h3>Results</h3> From a total of 99 pregnancies data was available for 76 infants. All 15 infants born to HBeAg positive mothers were given HBIG at birth. 7 mothers had a HBV DNA &gt; 107 IU/ml. 2 were treated with antiviral therapy during pregnancy. 58 (76.3%) infants received a full vaccination course. Only 35 (54.7%) of the 64 infants who should have had their post-vaccination status checked to date have had this completed. 34 (97.1%) had an adequate response to vaccination. One infant (who received 3 vaccinations) is HBsAg positive with a viral load of 5.4 × 103 iu/ml. The mother was HBeAg negative with a viral load of 1.7 × 103 iu/ml. <h3>Conclusion</h3> HBIG was administered appropriately to the infants at highest risk of vertical transmission of HBV. However, completion of the 4 dose HBV vaccination in infants was suboptimal postpartum and post- vaccination testing was inadequate. Efforts to improve this are now in place and include: prospective data collection to improve quality of data; development of a central reminder system to advise family doctors 2 weeks before each vaccination dose is due and ensure this is completed; and introduction of dry blood spot testing of the infants to improve the acceptability of testing. <h3>Disclosure of Interest</h3> None Declared
Re: Interpreting Preeursor Studies: What Polyp Trials Tell Us About Large-Bowel Cancer
Authors: JUDITH S. JACOBSON, ALFRED I. NEUGUT
Journal: JNCI Journal of the National Cancer Institute (1994)

Journal Article Re: Interpreting Preeursor Studies: What Polyp Trials Tell Us About Large-Bowel Cancer Get access JUDITH S. JACOBSON, JUDITH S. JACOBSON Search for other works by this author on: Oxford Academic PubMed Google Scholar ALFRED I. NEUGUT ALFRED I. NEUGUT Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 86, Issue 21, 2 November 1994, Page 1648, https://doi.org/10.1093/jnci/86.21.1648 Published: 02 November 1994
Outcome after Maternal Varicella Infection in the First 20 Weeks of Pregnancy
Authors: Anne L. Pastuszak, Maurice Levy, Betsy Schick, Carol Zuber, Marcia Feldkamp, Johnathan Gladstone, Fanny Bar-Levy, Elaine Jackson, Alan Donnenfeld, Wendy Meschino, Gideon Koren
Journal: New England Journal of Medicine (1994)

Infection with the varicella-zoster virus during pregnancy can produce an embryopathy characterized by limb hypoplasia, eye and brain damage, and skin lesions. The risk is greatest when infection occurs during the first 20 weeks of pregnancy, but the magnitude of the risk is uncertain.
Abstract 3628: JNJ-38877605: A selective oral Met inhibitor for the treatment of cancer
Authors: Peter King, Boud Janssens, Tinne Verhulst, Richard Argent, Rajendra Kumari, Susan Watson, Luc Andries, Laurence Mevellec, Martin Page, Tim Perera
Journal: Cancer Research (2010)

Abstract JNJ-38877605 is a potent and selective Met receptor tyrosine kinase inhibitor that has substantial pre-clinical antitumor activity. We recently described JNJ-38877605 as an ATP-competitive, inhibitor of the catalytic activity of Met kinase (IC50 4 nM) with a unique binding mode that leads to selectivity, exhibiting a 600-fold selectivity (vs cFMS IC50 2.6μM; the next potently inhibited kinase) for Met compared with a panel of 250 diverse tyrosine and serine-threonine kinases. Previously, JNJ-38877605 was shown to inhibit Met phosphorylation in tumor xenografts up to 16 h following a single oral dose, and that inhibition of receptor phosphorylation was associated with dose-dependent tumor growth inhibition. Herein we describe the activity of JNJ-38877605, on a broader range of preclinical solid tumor xenograft models, at doses below MTD and with different schedules of administration. In addition, we now also show data with primary patient-tumor derived xenografts where we have dosed JNJ-39977605 at the MTD using gastric, colorectal and liver metastatic (derived from primary CRC) samples. JNJ-38877605 was observed to induce significant tumor regression in large well established MET gene amplified gastric cancer models and in Met pathway activated (autocrine or paracrine) models. Significant growth inhibition was achieved when dosing JNJ-38877605 at MTD (and lower doses) with T/C &amp;lt; 42% in tumors of MKN-45, GTL-16, SNU-5 and Kato II met gene amplified models. Significant inhibition was also observed in K-ras mt (dependent) NCI-H441 NSCLC xenografts. Regression of U87 MG PTEN negative glioblastoma tumors (autocrine loop), grown either as subcutaneous or orthotopic models was also observed. Using primary patient derived xenograft models, we have shown that differential expression of the c-Met/HGF axis and epithelial-mesenchymal transition (EMT)-related gene markers between primary colorectal carcinomas and liver metastases in primary tissue, play a role in the activity of this compound in vivo. The strong preclinical properties of the JNJ-38877605 compound has resulted in the selection of this potent and uniquely selective Met inhibitor for clinical evaluation. JNJ-38877605 is currently in Phase I clinical trials. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3628.
P250In search for novel prognostic markers for coronary artery disease
Authors: M Popescu, CS Stancu, D Deleanu, L Niculescu, N Simionescu, A Vlad, AC Popescu, D Dimulescu, AV Sima
Journal: Cardiovascular Research (2014)

Purpose: Searching for new biomarkers to predict the progress of coronary artery disease (CAD), we studied the evolution of lipid and inflammatory parameters, along with five mi-RNAs, in plasma of CAD patients under treatment for 1 year.
P16.12 * BRAIN LOCATIONS INVOLVED IN BASELINE COGNITIVE FUNCTIONING OF PATIENTS WITH GLIOMA BEFORE THERAPY
Authors: E. J. J. Habets, E. J. Hendriks, M. J. B. Taphoorn, F. Barkhof, W. P. Vandertop, P. C. D. W. Hamer, M. Klein
Journal: Neuro-Oncology (2014)

INTRODUCTION: Cognition is often affected in patients with brain tumors. Apart from language function, direct tumor effects on discrete cognitive functions have barely been studied. In this study, we quantify baseline functioning in seven cognitive domains and identify brain locations involved in these cognitive domains using tumor localization maps (TLMs), which is a new approach. METHODS: Adult patients with glioma treated at the VU University Medical Center between 2006-2011 with available preoperative neuropsychological assessment were included. Cognition was tested for verbal memory, visuospatial memory, working memory, attention, executive functioning, information processing speed, and visuoconstructive abilities. Cognitive performance was compared to healthy controls, matched for age, sex, and educational level. Tumor volumes for TLMs were segmented on MRI fluid attenuated inversion recovery (FLAIR) hyperintense signal abnormality for low-grade gliomas, and MRI T1 contrast-enhanced abnormality for high-grade gliomas. For each cognitive domain, we applied TLMs to link cognitive performance with location throughout the brain at 1 mm resolution. Considerations for spatial dependence and multiple comparisons were taken into account. PRELIMINARY RESULTS: Seventy-four patients (7 with WHO grade I, 43 with grade II, 12 with grade III, and 10 with grade IV glioma, and 2 with other histology) were included so far. Mean age of patients was 40 years. Preoperative cognitive functioning was significantly impaired in five of seven domains compared to healthy controls. Most frequently affected were attentional function and working memory capacity (30% and 21% of patients, respectively). No differences in cognitive domain scores were observed between patients with low-grade and high-grade glioma. Tumor localization maps are currently being processed and statistically compared voxel-wise for each of the seven cognitive domains. Preliminary results of the TLMs demonstrate that performance in specific cognitive domains is associated with specific brain tumor locations. CONCLUSION: Empirical evidence on location of cognition can be used for optimizing brain tumor surgery and be integrated in counseling and cognitive rehabilitation for patients with newly-diagnosed glioma.
AB0186 BAFF levels in patients with ankylosing spondylitis and response to anti-tumor necrosis factor treatment
Authors: F. Niederer, A. Scherer, G. Tamborrini, B.A. Michel, R.E. Gay, S. Gay, D. Kyburz, A. Ciurea
Journal: Annals of the Rheumatic Diseases (2012)

<h3>Background</h3> Although B cells are not commonly associated with the pathogenesis of ankylosing spondylitis (AS), some findings corroborate their potential role in this chronic inflammatory rheumatic disease. Dense infiltrations of B cells are found in the spine of patients with active inflammation. Furthermore, tumor necrosis factor-blocker treatment naïve AS patients showed a good treatment response to B cell depletion with Rituximab. As B-cell activating factor (BAFF) is a potent B cell survival and maturation factor, we analyzed BAFF serum levels in AS patients before and after TNF-alpha inhibition. <h3>Objectives</h3> To determine whether levels of BAFF are elevated or relate to disease activity and response to treatment in patients with ankylosing spondylitis. <h3>Methods</h3> Serum samples were obtained from 49 patients with definite AS as well as from 35 healthy controls. TNF-alpha inhibition with infliximab (n=20) or adalimumab (n=15) was initiated in a proportion of patients with BASDAI &gt;4, according to the decision of the treating rheumatologist and serum was obtained again after 3 months in these subjects. BAFF levels were assessed by enzyme-linked immunosorbent assay (R&amp;D Systems). <h3>Results</h3> Baseline BAFF levels were lower in AS patients compared with healthy controls (median 1.1 ng/ml [5th-95th percentile: 1–1.9] vs 1.5 ng/ml [5th-95th 0.8–2.0] respectively; p=0.002). Only in 3/49 AS patients BAFF levels exceeded slightly the upper cutoff limit of 2.1 ng/ml (corresponding to the mean +2SD of the normal sera). Baseline BAFF levels did not correlate with BASDAI, CRP, HLA-B27 positivity, disease duration or co-medication with DMARDS. The median BAFF levels increased modestly 3 months after initiation of anti-TNF treatment, from 1.06 ng/ml to 1.38 ng/ml (Wilcoxon paired sign rank test 95% CI of increase: +0.09;+0.39, p=0.003) and nearly reached levels observed in healthy controls. <h3>Conclusions</h3> BAFF levels are not elevated in AS patients and do not correlate with disease activity parameters. These findings do not support the use of BAFF-targeted treatment strategies in AS patients not responding adequately to conventional treatment or TNF-alpha inhibition. <h3>Disclosure of Interest</h3> F. Niederer: None Declared, A. Scherer: None Declared, G. Tamborrini: None Declared, B. Michel: None Declared, R. Gay: None Declared, S. Gay: None Declared, D. Kyburz: None Declared, A. Ciurea Grant/Research support from: Abbott
Abstract 2003: STAT3 is a critical mediator of the pro-survival effect of Bcl-2-Rac1 interaction in human cancer cells
Authors: Jia Kang, Shireen Vali, Shweta Kapoor, Taher Abbasi, Shazib Pervaiz
Journal: Cancer Research (2012)

Abstract We recently showed that Bcl-2 overexpression induced a pro-oxidant intracellular milieu resulting in an inhibition of apoptotic execution and that reversing the pro-oxidant milieu by inhibiting intracellular superoxide production sensitized Bcl-2-overexpressing cells to apoptotic stimuli. We provide evidence that the small GTPase Rac1 is functionally involved since gene silencing and functional inhibition of Rac1 blocked Bcl-2-mediated increase in intracellular superoxide production in tumor cells. A co-localization and physical interaction between the two proteins were observed, which could be blocked by the BH3 mimetics as well as by synthetic Bcl-2 BH3 domain peptides both in vitro and in vivo. The Bcl-2 BH3 peptides as well as silencing and functional inhibition of Rac1 reversed intracellular superoxide levels and overcame Bcl-2-mediated drug resistance in human leukemia and cervical cancer cells, demonstrating that this interaction is functionally relevant. Notably, the interaction was observed in primary cells from patients diagnosed with B-cell lymphoma with Bcl-2 overexpression but not in noncancerous tissue. Furthermore, computer simulation driven virtual predictive experiments based on the protein pathway dynamic network created by Cellworks Group Inc. were carried out to study the functional implication of this interaction. An HCT116 human colorectal cancer cell line with KRAS over-activation, PI3K overexpression, CDKN2A deletion, β-catenin overexpression and Bcl-2 overexpression was created as a base line. Phenotypic indices of angiogenesis, proliferation, viability, metastasis as well as tumor volume were all found to be amplified in a variant cell line when Rac1 was overexpressed based on the above computer modeled HCT116. Strikingly, the expression levels of both STAT3 and β-catenin were significantly upregulated in the variant cell line; however upon Rac1 or Bcl-2 knockdown in both the base and the variant cell lines, apoptotic markers such as Bax, caspase 3 and cleaved PARP1 were amplified while STAT3 and β-catenin were significantly down-regulated. Intrigued by these predictions, we set out to verify the correlation between STAT3 signaling and Bcl-2-Rac1 interaction. Interestingly, there is indeed a strong correlation between the activation status of STAT3 (pY705) and Bcl-2 expression as well as Rac1 activation status. Furthermore, STAT3 was found to be localized to mitochondria and our preliminary results suggest an association with Bcl-2. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2003. doi:1538-7445.AM2012-2003